论文部分内容阅读
目的回顾性分析紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌(TNBC)的疗效。方法术前行4个周期紫杉联合表柔比星新辅助化疗方案治疗的乳腺癌患者151例,依据用药情况,47例作为TNBC组,104例作为对照组。比较2组患者反应率及术后远期疗效。结果 2组客观反应率差别无统计学意义(P>0.05);病理完全缓解,TNBC组显著高于对照组(34 vs 16,P<0.05)。2组随访期间死亡患者分别为34,13,但死亡风险无明显差别(HR=1.39,P>0.05)。结论 TNBC组患者更易从新辅助化疗中获完全缓解;但2组远期疗效无明显差别。
Objective To retrospectively analyze the efficacy of paclitaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative breast cancer (TNBC). Methods 151 cases of breast cancer were treated with docetaxel and epirubicin neoadjuvant chemotherapy 4 weeks before surgery. According to the medication, 47 cases were treated as TNBC group and 104 cases as control group. The response rate and postoperative long-term efficacy were compared between the two groups. Results There was no significant difference in objective response rate between the two groups (P> 0.05). The pathology was completely relieved. The TNBC group was significantly higher than the control group (34 vs 16, P <0.05). There were no significant differences in the risk of death between the two groups (34, 13, respectively) during the follow-up (HR = 1.39, P> 0.05). Conclusions Patients in the TNBC group are more likely to achieve complete remission from neoadjuvant chemotherapy; however, there is no significant difference in long-term efficacy between the two groups.